BioCatalyst

Solriamfetol 75mg, 150 mg, or 300 mg — catalyst calendar

1 verified catalyst event(s) referencing Solriamfetol 75mg, 150 mg, or 300 mg, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 4mo
ESTIMATED
 READOUT
Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
Phase 3 · Binge-Eating Disorder
 AXSM Axsome Therapeutics, Inc. Solriamfetol 75mg, 150 mg, or 300 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.